Home » Interviews » INTERVIEW: Microsaic Systems plc Agreement with Global Partner
Microsaic Systems plc

INTERVIEW: Microsaic Systems plc Agreement with Global Partner

Microsaic Systems plc (LON:MSYS) CEO Glenn Tracey joins DirectorsTalk to discuss the signing of a research agreement with a global partner in biopharma. Glenn provides us with some background to the deal, explains what a biopharmaceutical is, talks about the value of the biologics market and tells us why they are seeing the need for in-process mass spectrometry for biologics that perhaps wouldn’t see for traditional drugs.

Microsaic Systems plc is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry (“MS”) instruments that are designed to improve the efficiency of pharmaceutical R&D. The Company is working with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors. The company’s core product, the 4000 MiD®, is one of the smallest MS systems in the world, retaining the functionality of larger conventional MS systems, is easier to use by non-specialists, consumes less energy and has lower running costs.

You might also find these articles of interest:

Register here to be notified of future articles like this
Get all our broker ratings on Twitter as they are published!